Effect of Systemic Urokinase Infusion After Lower Limb Percutaneous Transluminal Angioplasty on Limb Salvage Rate in Patients with Late-stage Critical Limb Ischemia

Yen, Hsu-Ting; Hsieh, Ming‐Ju; Wu, Cheng-Ching; Lee, F.-Y.

doi:10.1016/j.ejvs.2014.04.006

Cited by 3 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In similar studies, the incidence was 50e65% for ischaemic heart disease and included patients with cardiac issues beyond previous acute coronary syndrome. 28,32,33 All patients had ischaemic wounds, and compared with the literature these wounds were complex. There were infection associated lesions (D subtype of UTWSC) in 76.8% of cases in the SV group and in 64.2% of cases in the MV group.…”

Section: Discussionmentioning

confidence: 99%

Infrapopliteal Angioplasty of One or More than One Artery for Critical Limb Ischaemia: A Randomised Clinical Trial

Biagioni

Nasser

et al. 2018

European Journal of Vascular and Endovascular Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Infrapopliteal Angioplasty of One or More than One Artery for Critical Limb Ischaemia: A Randomised Clinical Trial

Biagioni

Nasser

et al. 2018

European Journal of Vascular and Endovascular Surgery

View full text Add to dashboard Cite

show abstract

“…To date, no pharmacological treatment has been verified as capable of preventing peripheral arterial diseases (e.g., limb ischemia) from leading to amputations and mortality [ 3 , 4 ]. Endovascular intervention to channelize the blocked blood vessels or surgical bypass is the current treatment for patients with critical limb ischemia [ 5 , 6 ], but these attempts are apparently infeasible when applied to complicated late-stage limb ischemia [ 7 , 8 ]. Therefore, the development of a novel therapeutic approach to address critical limb ischemia is urgently required.…”

Section: Introductionmentioning

confidence: 99%

Gene therapy by virus-like self-spooling toroidal DNA condensates for revascularization of hindlimb ischemia

Wang,

Liu,

Tong

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Peripheral arterial diseases (PAD) have been reported to be the leading cause for limb amputations, and the current therapeutic strategies including antiplatelet medication or intervene surgery are reported to not clinically benefit the patients with high-grade PAD. To this respect, revascularization based on angiogenetic vascular endothelial growth factor (VEGF) gene therapy was attempted for the potential treatment of critical PAD. Aiming for transcellular delivery of VEGF-encoding plasmid DNA (pDNA), we proposed to elaborate intriguing virus-like DNA condensates, wherein the supercoiled rigid micrometer-scaled plasmid DNA (pDNA) could be regulated in an orderly fashion into well-defined nano-toroids by following a self-spooling process with the aid of cationic block copolymer poly(ethylene glycol)-polylysine at an extraordinary ionic strength (NaCl: 600 mM). Moreover, reversible disulfide crosslinking was proposed between the polylysine segments with the aim of stabilizing these intriguing toroidal condensates. Pertaining to the critical hindlimb ischemia, our proposed toroidal VEGF-encoding pDNA condensates demonstrated high levels of VEGF expression at the dosage sites, which consequently contributed to the neo-vasculature (the particularly abundant formation of micro-vessels in the injected hindlimb), preventing the hindlimb ischemia from causing necrosis at the extremities. Moreover, excellent safety profiles have been demonstrated by our proposed toroidal condensates, as opposed to the apparent immunogenicity of the naked pDNA. Hence, our proposed virus-like DNA condensates herald potentials as gene therapy platform in persistent expressions of the therapeutic proteins, and might consequently be highlighted in the management of a variety of intractable diseases.

show abstract

Current Phase II drugs under investigation for the treatment of limb ischemia

Spiliοpoulos

Kitrou

Κατσάνος

et al. 2015

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Novel endovascular technologies combining angioplasty and local drug-delivery continuously improve and will come to be standard of practice for the management of limb ischemia, while new antithrombotic agents will further improve outcomes. Therapeutic angiogenesis represents a safe and promising treatment option. The combination of revascularization with microcirculation improvement induced by gene or stem cell therapy could enhance limb salvage.

show abstract

Effect of Systemic Urokinase Infusion After Lower Limb Percutaneous Transluminal Angioplasty on Limb Salvage Rate in Patients with Late-stage Critical Limb Ischemia

Cited by 3 publications

References 22 publications

Infrapopliteal Angioplasty of One or More than One Artery for Critical Limb Ischaemia: A Randomised Clinical Trial

Infrapopliteal Angioplasty of One or More than One Artery for Critical Limb Ischaemia: A Randomised Clinical Trial

Gene therapy by virus-like self-spooling toroidal DNA condensates for revascularization of hindlimb ischemia

Current Phase II drugs under investigation for the treatment of limb ischemia

Contact Info

Product

Resources

About